Although this may be explained in part by more rapid loss of endogenous insulin secretion in non‐intensively treated participants 11, it may also relate to reductions in hypoglycaemia risk associated with preserved C‐peptide allowing intensification of treatment to a tighter level of glycaemic control. This evidence concerns the gene INS and Hypoglycemia.